Cell cycle-dependent antagonistic interactions between paclitaxel and γ-radiation in combination therapy

Clinical Cancer Research

Volumn 10, Issue 14, 2004, Pages 4848-4857

  Sui, Meihua ^a   Dziadyk, Jennifer M ^a   Zhu, Xueming ^a   Fan, Weimin ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN B1; DNA FRAGMENT; DOXORUBICIN; I KAPPA B ALPHA; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER THERAPY; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG POTENTIATION; FLOW CYTOMETRY; GAMMA RADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; FLOW CYTOMETRY; G2 PHASE; GAMMA RAYS; HUMANS; I-KAPPA B PROTEINS; MITOSIS; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS; UP-REGULATION;

EID: 3242717580     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0707     Document Type: Article

References (44)

1. Luck HJ, Roche H. Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Crit Rev Oncol Hematol 2002;44:S15-30.
2. Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 2003;13:142-7.
3. Sunwoo JB, Herscher LL, Kroog GS, et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 2001;19:800-11.
4. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond) 1979;277:665-7.
5. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-5.
6. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 1999;57:1215-21.
7. Terasima T, Tolmach LJ. Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophys J 1963;3:11-33.
8. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966;29:450-74.
9. Withers HR, Mason K, Reid BO, et al. Response of mouse intestine to neutrons and gamma rays in relation to dose fractionation and division cycle. Cancer (Phila) 1974;34:39-47.
10. Raitanen M, Rantanen V, Kulmala J, et al. Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines. Int J Cancer 2002;97:853-7.
11. Gupta N, Hu LJ, Deen DF. Cytotoxicity and cell-cycle effects of paclitaxel when used as a single agent and in combination with ionizing radiation. Int J Radiat Oncol Biol Phys 1997;37:885-95.
12. Jaakkola M, Rantanen V, Grenman S, Kulmala J, Grenman R. In vitro concurrent paclitaxel and radiation of four vulvar squaraous cell carcinoma cell lines. Cancer (Phila) 1996;77:1940-6.
13. Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 1994;54:3506-10.
14. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells J Natl Cancer Inst (Bethesda) 1994;86:441-6.
15. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD. Investigation of Taxol as a potential radiation sensitizer. Cancer (Phila) 1993;71:3774-8.
16. Loprevite M, Favoni RE, de Cupis A, et al. Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. Lung Cancer 2001;33:27-39.
17. Ingram ML, Redpath JL. Subadditive interaction of radiation and Taxol in vitro. Int J Radiat Oncol Biol Phys 1997;37:1139-44.
18. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996;56:1842-50.
19. Milross CG, Mason KA, Hunter NR, et al. Enhanced radioresponse of paclitaxel-sensitive and -resistant tumours in vivo. Eur J Cancer 1997;33:1299-308.
20. Safran H, Rathore R. Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer. Crit Rev Oncol Hematol 2002;43:57-62.
21. Bellon JR, Lindsley KL, Ellis GK, et al. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys 2000;48:393-7.
22. Formenti SC, Symmans WF, Volm M, et al. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 1999;9(Suppl 1):34-42.
23. Dunne AL, Price ME, Mothersill C, et al. Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells. Br J Cancer 2003;89:2277-83.
24. Cheng L, Zheng S, Raghunathan K, et al. Characterisations of Taxol-induced apoptosis and altered gene expression in human breast cancer cells. Cell Pharmacol 1995;2:249-57.
25. Zeng S, Chen YZ, Fu L, Johnson KR, Fan W. In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin Cancer Res 2000;6:3766-73.
26. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
27. Fan W, Cheng L, Norris JS, Willingham MC. Glucocorticoids selectively inhibit Taxol-induced apoptosis in a human breast cancer cell line. Cell Pharmocol 1996;3:435-40.
28. Johnson KR, Wang L, Miller MC III, Willingham MC, Fan W. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res 1997;3:1739-45.
29. 1-S arresting agents observed in experimental combination therapy. Clin Cancer Res 1999;5:2559-65.
30. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-11.
31. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
32. Schandl CA, Priest DG, Willingham MC. Phosphorylation of bcl-2 is a cell-cycle regulated event. Cell Pharmacol 1996;3:367-72.
33. Huang Y, Johnson KR, Norris JS, Fan W. Nuclear factor-kappa B/Ikappa B signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 2000;60:4426-32.
34. Huang Y, Fang Y, Dziadyk JM, Norris JS, Fan W. The possible correlation between activation of NF-kappa B/Ikappa B pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis. Oncol Res 2002;13:113-22.
35. cdc2. Cell 1989;58:833-46.
36. 2 delay, revealing a potential checkpoint in early mitosis. Cancer Res 2002;62:241-50.
37. cdc2. Cell 1991;67:197-211.
38. cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13- acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ 1998;9:23-9.
39. Iliakis G. Cell cycle regulation in irradiated and nonirradiated cells. Semin Oncol 1997;24:602-15.
40. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-90.
41. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987;34:155-66.
42. Ferguson LR, Baguley BC. Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Mutat Res 1996;355:91-101.
43. Ramachandran C, Samy TS, Huang XL, Yuan ZK, Krishan A. Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells. Biochem Pharmacol 1993;45:1367-71.
44. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U. Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκB-α. Proc Natl Acad Sci USA 1993;90:2532-6.